Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Jonathan M. Traxler who wrote (1175)	3/2/1998 7:37:00 PM
From: D.Right	Read Replies (2) \| Respond to of 2173

JNJ had brought three things to the table for AMLN: money, marketing power and endorsement. Money is replaceable, marketing power is replaceable too (with money, of course) but endorsement is not replaceable right away. The confidence of investors can only come back later with more positive clinical trial III data. The only good news is JNJ has given back all the right of pramlintide to AMLN, it is like they donated more than $100m for pramlintide development and gave up (they still have to pay for another two quarters to AMLN, maybe around $20m according to this quarter's number). It is really hard to believe. Remember, Lilly did the same thing with AGPH's AIDS drug earlier. Hopefully, AMLN can come back strong in the future like AGPH did. Bad day indeed. It is not the end of AMLN though. D.Right